|
EP2359865B1
(en)
|
2005-04-07 |
2013-10-02 |
The Trustees of The University of Pennsylvania |
Method of increasing the function of an AAV vector
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
IL297919A
(en)
*
|
2013-07-22 |
2023-01-01 |
Childrens Hospital Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
EP3851537B1
(en)
|
2014-04-25 |
2023-12-27 |
Genethon |
Treatment of hyperbilirubinemia
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
RU2716422C2
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
CN112410339A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
US10081659B2
(en)
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
AU2016260401B2
(en)
*
|
2015-05-14 |
2022-05-19 |
St. Jude Children's Research Hospital, Inc. |
Nucleic acid molecules containing spacers and methods of use thereof
|
|
IL256517B2
(en)
|
2015-06-23 |
2024-06-01 |
Childrens Hospital Philadelphia |
Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
CN108137655B
(zh)
|
2015-09-28 |
2022-04-22 |
北卡罗来纳-查佩尔山大学 |
逃避抗体的病毒载体的方法和组合物
|
|
PE20231949A1
(es)
*
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
|
BR112018007453A2
(pt)
|
2015-11-05 |
2018-10-23 |
Bamboo Therapeutics Inc |
genes modificados de ataxia de friedreich e vetores para a terapia gênica
|
|
SG11201804400SA
(en)
*
|
2015-12-01 |
2018-06-28 |
Spark Therapeutics Inc |
Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
|
|
US10385320B2
(en)
|
2015-12-02 |
2019-08-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
US10406244B2
(en)
|
2015-12-02 |
2019-09-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
AAV vectors with expanded packaging capacity
|
|
CA3007330A1
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of crigler-najjar syndrome
|
|
US20180363000A1
(en)
*
|
2015-12-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Aav-anti pcsk9 antibody constructs and uses thereof
|
|
EP3417055B1
(en)
|
2016-02-16 |
2021-10-13 |
The Board of Trustees of the Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
|
|
EP3436576A4
(en)
*
|
2016-03-30 |
2019-10-30 |
Spark Therapeutics, Inc. |
CELL LINE FOR RECOMBINANT PROTEIN AND / OR VIRUS VECTOR PRODUCTION
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
CA3252099A1
(en)
|
2016-05-18 |
2025-06-05 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
CN109831916B
(zh)
|
2016-05-18 |
2023-07-21 |
沃雅戈治疗公司 |
治疗亨廷顿氏舞蹈病的组合物和方法
|
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
MX2019000962A
(es)
*
|
2016-07-26 |
2019-08-01 |
Biomarin Pharm Inc |
Novedosas proteinas de la capside del virus adenoasociado.
|
|
EP3506817A4
(en)
|
2016-08-30 |
2020-07-22 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
IL319481A
(en)
|
2016-09-12 |
2025-05-01 |
Inst Nat Sante Rech Med |
Variants of acid alpha-glucosidase and their uses
|
|
EP3293260A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293203A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
JP2019537576A
(ja)
*
|
2016-11-04 |
2019-12-26 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ |
神経変性疾患を処置するための遺伝子移入用組成物、遺伝子導入法、及び遺伝子導入の使用
|
|
WO2018131551A1
(ja)
|
2017-01-13 |
2018-07-19 |
学校法人自治医科大学 |
肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのａａｖベクター
|
|
WO2018162748A1
(en)
|
2017-03-10 |
2018-09-13 |
Genethon |
Treatment of glycogen storage disease iii
|
|
WO2018170310A1
(en)
*
|
2017-03-15 |
2018-09-20 |
The University Of North Carolina At Chapel Hill |
Polyploid adeno-associated virus vectors and methods of making and using the same
|
|
US10550405B2
(en)
|
2017-03-15 |
2020-02-04 |
The University Of North Carolina At Chapel Hill |
Rational polyploid adeno-associated virus vectors and methods of making and using the same
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
WO2018213278A1
(en)
*
|
2017-05-15 |
2018-11-22 |
The Trustees Of Columbia University In The City Of New York |
Reprogramming metabolism by inhibiting vhl for treatment of neurodegeneration
|
|
BR112019025792A2
(pt)
|
2017-06-07 |
2020-07-07 |
Spark Therapeutics, Inc. |
agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
AU2018304194B2
(en)
*
|
2017-07-17 |
2025-02-27 |
Spark Therapeutics, Inc. |
Apheresis methods and uses
|
|
AU2018320849A1
(en)
*
|
2017-08-25 |
2020-03-05 |
Ovid Therapeutics Inc. |
Recombinant adeno-associated vectors
|
|
MX2020003042A
(es)
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN119242711A
(zh)
|
2017-10-16 |
2025-01-03 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症（als）的治疗
|
|
BR112020014404A2
(pt)
|
2018-01-17 |
2020-12-29 |
Adrenas Therapeutics, Inc. |
Terapia gênica de vírus adenoassociado para deficiência de 21-hidroxilase
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
PE20212076A1
(es)
|
2018-02-01 |
2021-10-26 |
Homology Medicines Inc |
Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas
|
|
JP7467356B2
(ja)
|
2018-02-07 |
2024-04-15 |
ジェネトン |
ハイブリッド調節要素
|
|
US11306329B2
(en)
|
2018-02-19 |
2022-04-19 |
City Of Hope |
Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
|
|
CN112352050A
(zh)
*
|
2018-02-27 |
2021-02-09 |
宾夕法尼亚州大学信托人 |
新颖腺相关病毒（aav）载体、具有降低的衣壳脱酰胺化的aav载体及其用途
|
|
JP7304878B2
(ja)
*
|
2018-03-16 |
2023-07-07 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
キャプシド改変による組織特異的遺伝子送達の増加
|
|
EP3774853A1
(en)
|
2018-03-30 |
2021-02-17 |
The Board of Trustees of the Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
|
|
CA3094465A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
SG11202009451VA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
|
JP7406677B2
(ja)
|
2018-04-03 |
2023-12-28 |
ギンコ バイオワークス インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
AU2019249890B2
(en)
|
2018-04-05 |
2024-10-10 |
Association Institut De Myologie |
Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism
|
|
WO2019200016A1
(en)
|
2018-04-10 |
2019-10-17 |
President And Fellows Of Harvard College |
Aav vectors encoding clarin-1 or gjb2 and uses thereof
|
|
US20210363192A1
(en)
*
|
2018-04-27 |
2021-11-25 |
Spark Therapeutics, Inc. |
Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
|
|
US20210231560A1
(en)
|
2018-04-29 |
2021-07-29 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
WO2019216932A1
(en)
*
|
2018-05-07 |
2019-11-14 |
The University Of North Carolina At Chapel Hill |
Rational polyploid adeno-associated virus vectors and methods of making and using the same
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
BR112020023082A2
(pt)
|
2018-05-15 |
2021-02-09 |
Voyager Therapeutics, Inc. |
composições e métodos para o tratamento de doença de parkinson
|
|
US12070702B2
(en)
|
2018-06-14 |
2024-08-27 |
Regenxbio Inc. |
Anion exchange chromatography for recombinant AAV production
|
|
JP7548899B2
(ja)
|
2018-08-08 |
2024-09-10 |
ジェネトン |
糖原病ｉｉｉの処置のためのミニｇｄｅ
|
|
JP2021533757A
(ja)
|
2018-08-10 |
2021-12-09 |
リジェネクスバイオ インコーポレイテッド |
組換えａａｖ生成のためのスケーラブルな方法
|
|
US10842885B2
(en)
|
2018-08-20 |
2020-11-24 |
Ucl Business Ltd |
Factor IX encoding nucleotides
|
|
GB201813528D0
(en)
|
2018-08-20 |
2018-10-03 |
Ucl Business Plc |
Factor IX encoding nucleotides
|
|
CA3114621A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
EP3867412A1
(en)
|
2018-10-15 |
2021-08-25 |
REGENXBIO Inc. |
Method for measuring the infectivity of replication defective viral vectors and viruses
|
|
AU2019363593A1
(en)
*
|
2018-10-25 |
2021-04-29 |
Takeda Pharmaceutical Company Limited |
AAV triple-plasmid system
|
|
AU2019381803A1
(en)
*
|
2018-11-16 |
2021-06-10 |
AskBio Inc. |
Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal targeting sequence
|
|
CA3133453A1
(en)
|
2019-03-21 |
2020-09-24 |
Daniel Mccoy |
Recombinant adeno-associated virus vectors
|
|
WO2020198737A1
(en)
*
|
2019-03-28 |
2020-10-01 |
The General Hospital Corporation |
Engineered adeno-associated (aav) vectors for transgene expression
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
PL3953483T3
(pl)
|
2019-04-11 |
2024-04-22 |
Regenxbio Inc. |
Sposoby chromatografii wykluczania do charakteryzowania kompozycji rekombinowanych wirusów towarzyszących adenowirusom
|
|
MX2021012564A
(es)
|
2019-04-19 |
2022-01-18 |
Regenxbio Inc |
Formulaciones y métodos de vectores de virus adenoasociados.
|
|
EP3956354A1
(en)
|
2019-04-19 |
2022-02-23 |
Genethon |
Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
|
|
SG11202111414RA
(en)
|
2019-04-24 |
2021-11-29 |
Regenxbio Inc |
Fully-human post-translationally modified antibody therapeutics
|
|
BR112021021502A2
(pt)
*
|
2019-04-29 |
2022-07-19 |
Univ Pennsylvania |
Capsídeos de aav e composições contendo os mesmos
|
|
EP3967706A4
(en)
*
|
2019-05-08 |
2022-12-28 |
Center For Excellence In Brain Science And Intelligence Technology, Chinese Academy Of Sciences |
AAV MUTANT FOR EFFICIENT INFECTION OF SUPPORT CELLS
|
|
CN110205297A
(zh)
*
|
2019-05-15 |
2019-09-06 |
华北理工大学 |
一种重组脂肪干细胞及其重组方法
|
|
CA3144864A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
EP3996696A1
(en)
|
2019-07-09 |
2022-05-18 |
Genethon |
Treatment of glycogen storage disease (gsd)
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
US20220265853A1
(en)
|
2019-07-12 |
2022-08-25 |
Gene Therapy Research Institution Co., Ltd. |
Adeno-associated virus virion for gene transfer to human liver
|
|
EP4004214A1
(en)
|
2019-07-26 |
2022-06-01 |
RegenxBio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
RU2751592C2
(ru)
*
|
2019-08-22 |
2021-07-15 |
Общество С Ограниченной Ответственностью "Анабион" |
Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
|
|
US20220298514A1
(en)
*
|
2019-09-11 |
2022-09-22 |
Aav Gene Therapeutics, Inc. |
Aav-zyme and use for infusion replacement therapy
|
|
TW202128736A
(zh)
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療ｃ型尼曼—匹克病之腺相關病毒載體
|
|
WO2021078834A1
(en)
|
2019-10-22 |
2021-04-29 |
Genethon |
Chimeric acid-alpha glucosidase polypeptides and uses thereof
|
|
CN114555808A
(zh)
|
2019-10-22 |
2022-05-27 |
吉尼松公司 |
嵌合多肽及其用途
|
|
JP2023503850A
(ja)
*
|
2019-11-14 |
2023-02-01 |
バイオマリン ファーマシューティカル インコーポレイテッド |
肝臓特異的遺伝子療法ベクターによる遺伝性血管浮腫の治療
|
|
WO2021099394A1
(en)
|
2019-11-19 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
BR112022009895A2
(pt)
|
2019-11-28 |
2022-08-09 |
Regenxbio Inc |
Construtos de terapia de gene de microdistrofina e usos dos mesmos
|
|
CA3156611A1
(en)
|
2019-12-18 |
2021-06-24 |
Serge Braun |
Production of recombinant viral vectors from plant hairy roots
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
AR121201A1
(es)
|
2020-01-29 |
2022-04-27 |
Regenxbio Inc |
Tratamiento de mucopolisacaridosis iva
|
|
EP3892720A1
(en)
|
2020-04-06 |
2021-10-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
|
WO2021229255A1
(en)
|
2020-05-14 |
2021-11-18 |
Genethon |
Tools and method for preventing a a¥ neutralization by antibodies
|
|
EP3913060A1
(en)
|
2020-05-22 |
2021-11-24 |
Genethon |
Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
JP2023532923A
(ja)
*
|
2020-06-30 |
2023-08-01 |
チルドレンズ ナショナル メディカル センター |
骨格筋線維の修復を改善するためのリコンビナントヒト酸性スフィンゴミエリナーゼの使用
|
|
EP4179091A1
(en)
|
2020-07-10 |
2023-05-17 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Methods and compositions for treating epilepsy
|
|
CN116745409A
(zh)
|
2020-08-19 |
2023-09-12 |
萨雷普塔治疗公司 |
用于治疗雷特综合征的腺相关病毒载体
|
|
WO2022043280A1
(en)
|
2020-08-24 |
2022-03-03 |
Genethon |
C-terminal truncated gde for the treatment of glycogen storage disease iii
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
US20250326861A1
(en)
|
2020-09-15 |
2025-10-23 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
CA3193697A1
(en)
|
2020-10-07 |
2022-04-14 |
Joseph Bruder |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
WO2022081776A1
(en)
|
2020-10-13 |
2022-04-21 |
Kriya Therapeutics, Inc. |
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
|
|
EP4229204A1
(en)
|
2020-10-15 |
2023-08-23 |
F. Hoffmann-La Roche AG |
Nucleic acid constructs for simultaneous gene activation
|
|
JP2023546116A
(ja)
|
2020-10-15 |
2023-11-01 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｖａ ｒｎａ転写のための核酸構築物
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
AR123948A1
(es)
|
2020-10-28 |
2023-01-25 |
Regenxbio Inc |
ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
|
|
EP4237453A1
(en)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
US20230390418A1
(en)
|
2020-10-29 |
2023-12-07 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
MX2023005218A
(es)
|
2020-11-03 |
2023-05-16 |
Pfizer |
Metodos de purificacion de vectores de aav mediante cromatografia de intercambio anionico.
|
|
US20240067942A1
(en)
|
2020-12-09 |
2024-02-29 |
Genethon |
Lysosomal acid lipase variants and uses thereof
|
|
WO2022130172A1
(en)
|
2020-12-15 |
2022-06-23 |
Pfizer Inc. |
Hilic uplc-ms method for separating and analyzing intact adeno-associated virus capsid proteins
|
|
KR20230120128A
(ko)
|
2020-12-16 |
2023-08-16 |
리젠엑스바이오 인크. |
재조합 바이러스 입자의 생산 방법
|
|
AU2021404944A1
(en)
|
2020-12-23 |
2023-07-06 |
Pfizer Inc. |
Methods for purification of aav vectors by affinity chromatography
|
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
|
CA3205209A1
(en)
|
2021-01-21 |
2022-07-28 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
KR20230159837A
(ko)
|
2021-03-19 |
2023-11-22 |
아드레나스 테라퓨틱스, 인코포레이티드 |
21-하이드록실라제 결핍에 대한 유전자 요법
|
|
US20240307553A1
(en)
|
2021-04-01 |
2024-09-19 |
Pfizer Inc. |
Pharmaceutical compositions containing adeno-associated viral vector
|
|
JP2024515626A
(ja)
*
|
2021-04-16 |
2024-04-10 |
アスクレピオス バイオファーマシューティカル， インコーポレイテッド |
血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
|
|
TW202309293A
(zh)
|
2021-04-26 |
2023-03-01 |
美商銳進科斯生物股份有限公司 |
用於治療肌縮蛋白症(dystrophinopathy)之微小肌縮蛋白基因療法給藥
|
|
CA3216420A1
(en)
|
2021-04-26 |
2022-11-03 |
Seungil Han |
Adeno-associated viral vector capsids with improved tissue tropism
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
WO2022269466A1
(en)
|
2021-06-22 |
2022-12-29 |
Pfizer Inc. |
Production of adeno-associated virus vector in insect cells
|
|
EP4373947A1
(en)
|
2021-07-19 |
2024-05-29 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
AR126839A1
(es)
*
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
|
|
AR126840A1
(es)
*
|
2021-08-20 |
2023-11-22 |
Llc «Anabion» |
Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
EP4413018A1
(en)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
AU2022358779A1
(en)
|
2021-10-08 |
2024-04-18 |
Dyno Therapeutics, Inc. |
Capsid variants and methods of using the same
|
|
CN118660710A
(zh)
|
2021-10-20 |
2024-09-17 |
罗切斯特大学 |
用于年龄相关白质损失的竞争性治疗的分离神经胶质祖细胞
|
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
CA3236365A1
(en)
|
2021-11-02 |
2023-05-11 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
EP4215245A1
(en)
|
2022-01-19 |
2023-07-26 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
|
|
EP4465998A1
(en)
|
2022-01-21 |
2024-11-27 |
Astrazeneca Ireland Limited |
Gene therapy for gaucher disease
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
WO2023178053A1
(en)
|
2022-03-13 |
2023-09-21 |
Regenxbio Inc. |
Modified muscle-specific promoters
|
|
EP4499154A1
(en)
|
2022-03-25 |
2025-02-05 |
REGENXBIO Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
CN118974274A
(zh)
|
2022-04-13 |
2024-11-15 |
豪夫迈·罗氏有限公司 |
用于确定aav基因组的方法
|
|
EP4507741A1
(en)
|
2022-04-14 |
2025-02-19 |
RegenxBio Inc. |
Gene therapy for treating an ocular disease
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
US20250288697A1
(en)
|
2022-05-03 |
2025-09-18 |
Regenxbio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
AR129215A1
(es)
|
2022-05-03 |
2024-07-31 |
Regenxbio Inc |
Anticuerpos anti-complemento y agentes del complemento vectorizados y administración de estos
|
|
JP2025517987A
(ja)
|
2022-05-23 |
2025-06-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａａｖ粒子血清型およびａａｖ粒子負荷状態の識別のためのラマンベースの方法
|
|
AU2023278422A1
(en)
|
2022-06-03 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
CA3252764A1
(en)
|
2022-06-09 |
2023-12-14 |
Institut National de la Santé et de la Recherche Médicale |
GDE truncated at the N-terminal level for the treatment of type III glycogen storage disease
|
|
WO2024003687A1
(en)
|
2022-06-28 |
2024-01-04 |
Pfizer Inc. |
Nucleic acids encoding acid alpha-glucosidase (gaa) and vectors for gene therapy
|
|
CA3261054A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
PROCESS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLES
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
JP2025526697A
(ja)
|
2022-08-15 |
2025-08-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
組換えウイルスベクターに関連する有害作用の予防または緩和
|
|
WO2024038365A1
(en)
|
2022-08-16 |
2024-02-22 |
Pfizer Inc. |
Methods for purification of aav vectors by anion exchange chromatography
|
|
JP2025527658A
(ja)
|
2022-08-24 |
2025-08-22 |
リジェネックスバイオ インコーポレイテッド |
組換えアデノ随伴ウイルス及びその使用
|
|
KR20250067819A
(ko)
|
2022-09-12 |
2025-05-15 |
에프. 호프만-라 로슈 아게 |
핵산 포함 및 핵산 비포함 aav 입자를 분리하는 방법
|
|
EP4601710A2
(en)
|
2022-10-11 |
2025-08-20 |
RegenxBio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
EP4646478A1
(en)
|
2023-01-06 |
2025-11-12 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
WO2024163747A2
(en)
|
2023-02-02 |
2024-08-08 |
University Of Rochester |
Competitive replacement of glial cells
|
|
EP4662490A1
(en)
|
2023-02-07 |
2025-12-17 |
F. Hoffmann-La Roche AG |
Method for the detection of anti-aav particle antibodies
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
CN120835797A
(zh)
|
2023-03-21 |
2025-10-24 |
豪夫迈·罗氏有限公司 |
用于产生重组aav颗粒制备物的方法
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
CN120936723A
(zh)
|
2023-04-13 |
2025-11-11 |
豪夫迈·罗氏有限公司 |
改进的重组多腺苷酸化信号序列及其用途
|
|
WO2024233099A1
(en)
*
|
2023-05-05 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Labeling and anti-drug antibody assays for aav vectors
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024238867A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2025003477A1
(en)
|
2023-06-29 |
2025-01-02 |
Genethon |
N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025082618A1
(en)
|
2023-10-20 |
2025-04-24 |
Fuse Vectors Aps |
In vitro parvovirus capsid manufacturing
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2025250457A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Enhanced brain transduction by gene therapeutics
|
|
WO2025252480A1
(en)
|
2024-06-07 |
2025-12-11 |
F. Hoffmann-La Roche Ag |
Method for purifying plasmid dna
|